KRAS and pachyonychia congenita: They employed a 3 + 3 dose-escalation and accelerated titration design, enrolling advanced PC patients in a human phase I clinical trial to assess safety, tolerability, and biomarker changes, providing a safe and targeted treatment option for KRAS-mutant-driven PC.